<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02641067</url>
  </required_header>
  <id_info>
    <org_study_id>1439-051</org_study_id>
    <secondary_id>MK-1439-051</secondary_id>
    <nct_id>NCT02641067</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Pharmacokinetics of Doravirine (MK-1439) in Participants With Severe Renal Impairment (MK-1439-051)</brief_title>
  <official_title>An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of MK-1439 (Doravirine) in Subjects With Severe Renal Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effect of severe renal impairment on the pharmacokinetics of
      doravirine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 26, 2016</start_date>
  <completion_date type="Actual">May 25, 2016</completion_date>
  <primary_completion_date type="Actual">May 14, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve From 0 Hours to Infinity (AUC0-∞) of Doravirine</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 6, 12, 24, 48, 72 hours post-dose for all participants; and 96 hours post-dose for participants with severe renal impairment</time_frame>
    <description>Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Concentration of Doravirine at 24 Hours Postdose (C24)</measure>
    <time_frame>24 hours postdose</time_frame>
    <description>Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Doravirine</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 6, 12, 24, 48, 72 hours post-dose for all participants; and 96 hours post-dose for participants with severe renal impairment</time_frame>
    <description>Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve From 0 Hours to the Time of Last Quantifiable Sample of Doravirine (AUC 0-last)</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 6, 12, 24, 48, 72 hours post-dose for all participants; and 96 hours post-dose for participants with severe renal impairment</time_frame>
    <description>Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Observed Plasma Concentration (Tmax) of Doravirine</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 6, 12, 24, 48, 72 hours post-dose for all participants; and 96 hours post-dose for participants with severe renal impairment</time_frame>
    <description>Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Terminal Half-life (t1/2) of Plasma Doravirine</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 6, 12, 24, 48, 72 hours post-dose for all participants; and 96 hours post-dose for participants with severe renal impairment</time_frame>
    <description>Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Clearance of Plasma Doravirine After Extravascular Administration (CL/F)</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 6, 12, 24, 48, 72 hours post-dose for all participants; and 96 hours post-dose for participants with severe renal impairment</time_frame>
    <description>Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution of Plasma Doravirine During the Terminal Phase (Vz/F)</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 6, 12, 24, 48, 72 hours post-dose for all participants; and 96 hours post-dose for participants with severe renal impairment</time_frame>
    <description>Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Renal Impairment</condition>
  <arm_group>
    <arm_group_label>Severe Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with severe renal impairment receive a single oral dose of 100 mg doravirine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Matched Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy participants matched for age and weight receive a single oral dose of 100 mg doravirine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doravirine</intervention_name>
    <description>Following an overnight fast, a single coated tablet of 100 mg doravirine will be administered orally</description>
    <arm_group_label>Healthy Matched Control</arm_group_label>
    <arm_group_label>Severe Renal Impairment</arm_group_label>
    <other_name>MK-1439, PIFELTRO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  is a non-smoker or moderate smoker

          -  has a body mass index (BMI) ≥ 18.5 and ≤ 40.0 kg/m^2

          -  other than renal impairment, participant is judged to be in good health based on
             medical history, physical examination, vital signs, and laboratory safety tests

          -  female informed of the risks of pregnancy, agree not to become pregnant while
             participating in this study. Female of childbearing potential must either be sexually
             inactive for 14 days prior to dosing and throughout the study, or uses one acceptable
             birth control method

          -  female of non-childbearing potential must have undergone sterilization procedures at
             least 6 months prior to dosing.

          -  Participants with severe renal impairment only: has baseline estimated glomerular
             filtration rate (eGFR) &lt; 30 mL/min/1.73m^2

        Exclusion Criteria:

          -  is mentally or legally incapacitated or has significant emotional problems

          -  has a history or presence of clinically significant medical or psychiatric condition
             or disease

          -  has history or presence of alcoholism or drug abuse within the past 2 years

          -  has history or presence of hypersensitivity or idiosyncratic reaction to the study
             drug, any inactive ingredients, or related compounds

          -  has history or presence of renal artery stenosis

          -  has had a renal transplant or nephrectomy

          -  has rapidly fluctuating renal function as determined by historical measurements

          -  female is pregnant or lactating

          -  has positive results for the urine or saliva drug and urine or breath alcohol screen
             at screening or check-in

          -  has positive results at screening for human immunodeficiency virus (HIV), hepatitis B
             surface antigen (HBsAg), or hepatitis C virus (HCV)

          -  is unable to refrain from or anticipates the use of any drug, including prescription
             and non-prescription medications, herbal remedies, or vitamin supplements beginning 14
             days prior to dosing and throughout the study. Certain medications including those to
             treat kidney disease will be permitted. Other medications may be permitted following
             consultation with the Sponsor Clinical Monitor.

          -  is unable to refrain from or anticipates the use of inducers of cytochrome P450 3A
             (CYP3A) or permeability glycoprotein (P-gp) transporters for at least 28 days prior to
             dosing and throughout the study.

          -  has been on a diet incompatible with the on-study diet, within 28 days prior to
             dosing, and throughout the study

          -  has donated blood or had significant blood loss within 56 days prior to dosing

          -  has donated plasma within 7 days prior to dosing

          -  has participated in another clinical trial within 28 days prior to dosing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>December 23, 2015</study_first_submitted>
  <study_first_submitted_qc>December 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2015</study_first_posted>
  <results_first_submitted>September 26, 2018</results_first_submitted>
  <results_first_submitted_qc>September 26, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 8, 2019</results_first_posted>
  <last_update_submitted>September 26, 2018</last_update_submitted>
  <last_update_submitted_qc>September 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Severe Renal Impairment</title>
          <description>Participants with severe renal impairment received a single oral dose of 100 mg doravirine</description>
        </group>
        <group group_id="P2">
          <title>Healthy Matched Controls</title>
          <description>Healthy participants matched for age and weight received a single oral dose of 100 mg doravirine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Severe Renal Impairment</title>
          <description>Participants with severe renal impairment received a single oral dose of 100 mg doravirine</description>
        </group>
        <group group_id="B2">
          <title>Healthy Matched Controls</title>
          <description>Healthy participants matched for age and weight received a single oral dose of 100 mg doravirine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>19 to 49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50 to 59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 to 69 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <units>Kilogram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90.86" spread="17.409"/>
                    <measurement group_id="B2" value="90.93" spread="6.086"/>
                    <measurement group_id="B3" value="90.89" spread="12.599"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve From 0 Hours to Infinity (AUC0-∞) of Doravirine</title>
        <description>Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method.</description>
        <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 6, 12, 24, 48, 72 hours post-dose for all participants; and 96 hours post-dose for participants with severe renal impairment</time_frame>
        <population>All participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model.</population>
        <group_list>
          <group group_id="O1">
            <title>Severe Renal Impairment</title>
            <description>Participants with severe renal impairment received a single oral dose of 100 mg doravirine</description>
          </group>
          <group group_id="O2">
            <title>Healthy Matched Controls</title>
            <description>Healthy participants matched for age and weight received a single oral dose of 100 mg doravirine</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve From 0 Hours to Infinity (AUC0-∞) of Doravirine</title>
          <description>Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method.</description>
          <population>All participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model.</population>
          <units>μM•hr</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.5" lower_limit="47.4" upper_limit="87.8"/>
                    <measurement group_id="O2" value="45.1" lower_limit="33.2" upper_limit="61.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>1.43</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.00</ci_lower_limit>
            <ci_upper_limit>2.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Concentration of Doravirine at 24 Hours Postdose (C24)</title>
        <description>Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method.</description>
        <time_frame>24 hours postdose</time_frame>
        <population>All participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model.</population>
        <group_list>
          <group group_id="O1">
            <title>Severe Renal Impairment</title>
            <description>Participants with severe renal impairment received a single oral dose of 100 mg doravirine</description>
          </group>
          <group group_id="O2">
            <title>Healthy Matched Controls</title>
            <description>Healthy participants matched for age and weight received a single oral dose of 100 mg doravirine</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of Doravirine at 24 Hours Postdose (C24)</title>
          <description>Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method.</description>
          <population>All participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model.</population>
          <units>nM</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="943" lower_limit="710" upper_limit="1250"/>
                    <measurement group_id="O2" value="684" lower_limit="515" upper_limit="908"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>1.38</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) of Doravirine</title>
        <description>Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method.</description>
        <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 6, 12, 24, 48, 72 hours post-dose for all participants; and 96 hours post-dose for participants with severe renal impairment</time_frame>
        <population>All participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model.</population>
        <group_list>
          <group group_id="O1">
            <title>Severe Renal Impairment</title>
            <description>Participants with severe renal impairment received a single oral dose of 100 mg doravirine</description>
          </group>
          <group group_id="O2">
            <title>Healthy Matched Controls</title>
            <description>Healthy participants matched for age and weight received a single oral dose of 100 mg doravirine</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) of Doravirine</title>
          <description>Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method.</description>
          <population>All participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model.</population>
          <units>nM</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1580" lower_limit="1210" upper_limit="2080"/>
                    <measurement group_id="O2" value="1900" lower_limit="1450" upper_limit="2500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>0.83</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve From 0 Hours to the Time of Last Quantifiable Sample of Doravirine (AUC 0-last)</title>
        <description>Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method.</description>
        <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 6, 12, 24, 48, 72 hours post-dose for all participants; and 96 hours post-dose for participants with severe renal impairment</time_frame>
        <population>All participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model.</population>
        <group_list>
          <group group_id="O1">
            <title>Severe Renal Impairment</title>
            <description>Participants with severe renal impairment received a single oral dose of 100 mg doravirine</description>
          </group>
          <group group_id="O2">
            <title>Healthy Matched Controls</title>
            <description>Healthy participants matched for age and weight received a single oral dose of 100 mg doravirine</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve From 0 Hours to the Time of Last Quantifiable Sample of Doravirine (AUC 0-last)</title>
          <description>Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method.</description>
          <population>All participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model.</population>
          <units>μM•hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.5" spread="56.3"/>
                    <measurement group_id="O2" value="41.0" spread="29.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Observed Plasma Concentration (Tmax) of Doravirine</title>
        <description>Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method.</description>
        <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 6, 12, 24, 48, 72 hours post-dose for all participants; and 96 hours post-dose for participants with severe renal impairment</time_frame>
        <population>All participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model.</population>
        <group_list>
          <group group_id="O1">
            <title>Severe Renal Impairment</title>
            <description>Participants with severe renal impairment received a single oral dose of 100 mg doravirine</description>
          </group>
          <group group_id="O2">
            <title>Healthy Matched Controls</title>
            <description>Healthy participants matched for age and weight received a single oral dose of 100 mg doravirine</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Observed Plasma Concentration (Tmax) of Doravirine</title>
          <description>Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method.</description>
          <population>All participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="0.50" upper_limit="4.00"/>
                    <measurement group_id="O2" value="1.50" lower_limit="0.50" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Terminal Half-life (t1/2) of Plasma Doravirine</title>
        <description>Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method.</description>
        <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 6, 12, 24, 48, 72 hours post-dose for all participants; and 96 hours post-dose for participants with severe renal impairment</time_frame>
        <population>All participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model.</population>
        <group_list>
          <group group_id="O1">
            <title>Severe Renal Impairment</title>
            <description>Participants with severe renal impairment received a single oral dose of 100 mg doravirine</description>
          </group>
          <group group_id="O2">
            <title>Healthy Matched Controls</title>
            <description>Healthy participants matched for age and weight received a single oral dose of 100 mg doravirine</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Half-life (t1/2) of Plasma Doravirine</title>
          <description>Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method.</description>
          <population>All participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model.</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.02" spread="36.4"/>
                    <measurement group_id="O2" value="16.69" spread="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Clearance of Plasma Doravirine After Extravascular Administration (CL/F)</title>
        <description>Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method.</description>
        <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 6, 12, 24, 48, 72 hours post-dose for all participants; and 96 hours post-dose for participants with severe renal impairment</time_frame>
        <population>All participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model.</population>
        <group_list>
          <group group_id="O1">
            <title>Severe Renal Impairment</title>
            <description>Participants with severe renal impairment received a single oral dose of 100 mg doravirine</description>
          </group>
          <group group_id="O2">
            <title>Healthy Matched Controls</title>
            <description>Healthy participants matched for age and weight received a single oral dose of 100 mg doravirine</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Clearance of Plasma Doravirine After Extravascular Administration (CL/F)</title>
          <description>Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method.</description>
          <population>All participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model.</population>
          <units>Liter/hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.53" spread="63.9"/>
                    <measurement group_id="O2" value="5.38" spread="32.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Volume of Distribution of Plasma Doravirine During the Terminal Phase (Vz/F)</title>
        <description>Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method.</description>
        <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 6, 12, 24, 48, 72 hours post-dose for all participants; and 96 hours post-dose for participants with severe renal impairment</time_frame>
        <population>All participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model.</population>
        <group_list>
          <group group_id="O1">
            <title>Severe Renal Impairment</title>
            <description>Participants with severe renal impairment received a single oral dose of 100 mg doravirine</description>
          </group>
          <group group_id="O2">
            <title>Healthy Matched Controls</title>
            <description>Healthy participants matched for age and weight received a single oral dose of 100 mg doravirine</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution of Plasma Doravirine During the Terminal Phase (Vz/F)</title>
          <description>Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method.</description>
          <population>All participants who complied with the protocol sufficiently to ensure that generated data were likely to exhibit the effects of treatment, according to the underlying scientific model.</population>
          <units>Liters</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127" spread="40.9"/>
                    <measurement group_id="O2" value="129" spread="28.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 14 days after drug administration</time_frame>
      <desc>The population analyzed consisted of all participants who received at least 1 dose of study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Severe Renal Impairment</title>
          <description>Participants with severe renal impairment received a single oral dose of 100 mg doravirine</description>
        </group>
        <group group_id="E2">
          <title>Healthy Matched Control</title>
          <description>Healthy participants matched for age and weight received a single oral dose of 100 mg doravirine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor's policy on authorship is consistent with the requirements outlined in the ICH-Good Clinical Practice guidelines. In summary, authorship should reflect significant contribution to the design and conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

